TY - JOUR
T1 - KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival
AU - Hatami, Raheleh
AU - Sieuwerts, Anieta M.
AU - Izadmehr, Sudeh
AU - Yao, Zhong
AU - Qiao, Rui Fang
AU - Papa, Luena
AU - Look, Maxime P.
AU - Smid, Marcel
AU - Ohlssen, Jessica
AU - Levine, Alice C.
AU - Germain, Doris
AU - Burstein, David
AU - Kirschenbaum, Alexander
AU - DiFeo, Analisa
AU - Foekens, John A.
AU - Narla, Goutham
PY - 2013/1/23
Y1 - 2013/1/23
N2 - Metastasis is the major cause of cancer mortality. A more thorough understanding of the mechanisms driving this complex multistep process will aid in the identification and characterization of therapeutically targetable genetic drivers of disease progression. We demonstrate that KLF6-SV1, an oncogenic splice variant of the KLF6 tumor suppressor gene, is associated with increased metastatic potential and poor survival in a cohort of 671 lymph node-negative breast cancer patients. KLF6-SV1 overexpression in mammary epithelial cell lines resulted in an epithelial-to-mesenchymal-like transition and drove aggressive multiorgan metastatic disease in multiple in vivo models. Additionally, KLF6-SV1 loss-of-function studies demonstrated reversion to an epithelial and less invasive phenotype. Combined, these findings implicate KLF6-SV1 as a key driver of breast cancer metastasis that distinguishes between indolent and lethal early-stage disease and provides a potential therapeutic target for invasive breast cancer.
AB - Metastasis is the major cause of cancer mortality. A more thorough understanding of the mechanisms driving this complex multistep process will aid in the identification and characterization of therapeutically targetable genetic drivers of disease progression. We demonstrate that KLF6-SV1, an oncogenic splice variant of the KLF6 tumor suppressor gene, is associated with increased metastatic potential and poor survival in a cohort of 671 lymph node-negative breast cancer patients. KLF6-SV1 overexpression in mammary epithelial cell lines resulted in an epithelial-to-mesenchymal-like transition and drove aggressive multiorgan metastatic disease in multiple in vivo models. Additionally, KLF6-SV1 loss-of-function studies demonstrated reversion to an epithelial and less invasive phenotype. Combined, these findings implicate KLF6-SV1 as a key driver of breast cancer metastasis that distinguishes between indolent and lethal early-stage disease and provides a potential therapeutic target for invasive breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=84872703162&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3004688
DO - 10.1126/scitranslmed.3004688
M3 - Article
C2 - 23345610
AN - SCOPUS:84872703162
SN - 1946-6234
VL - 5
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 169
M1 - 169ra12
ER -